A 21-year-old male is using finasteride, minoxidil, and had a hair transplant to address lifelong thin, diffuse hair loss. Progress pictures show changes over two months.
Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.
User suggests rotating scalp 180 degrees to address hair loss. Others discuss sanity, ethics, and similar procedures like scalp reduction and hair transplants.
A person used hair fibers for 11 years to hide hair loss, which affected their social life. They had a hair transplant, improving their life, and recommend addressing hair loss directly.
The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.
A 14-month update on a FUE hair transplant, and the effects of male pattern baldness. People discussed products such as Minoxidil, finasteride, Kerastase Chronologiste shampoo and care oil, and RU58841 to help treat hair loss.
Adding an LLLT laser cap to a routine of finasteride, minoxidil, and ketoconazole shampoo significantly reduced hair shedding from 200+ hairs a day to around 80, improving scalp health. The user attributes the laser cap as the key factor in stabilizing hair loss after two years of using other treatments.
The user is experiencing shedding of thick, healthy hair after using KX826 0.5% for a month. They are concerned about losing coverage and are seeking others' experiences with regrowth.
The conversation discusses a small patch of missing hair and whether treatments like Minoxidil, finasteride, or RU58841 could help. The user is seeking advice on addressing this specific hair issue.
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.